Cargando…

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy

BACKGROUND: Biosimilars of filgrastim are in widespread clinical use in Europe. This phase III study compares biosimilar filgrastim (EP2006), with the US-licensed reference product, Neupogen(®), in breast cancer patients receiving (neo)adjuvant myelosuppressive chemotherapy (TAC). PATIENTS AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blackwell, K., Semiglazov, V., Krasnozhon, D., Davidenko, I., Nelyubina, L., Nakov, R., Stiegler, G., Singh, P., Schwebig, A., Kramer, S., Harbeck, N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551159/ https://www.ncbi.nlm.nih.gov/pubmed/26122726 http://dx.doi.org/10.1093/annonc/mdv281

Ejemplares similares

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli, Désirée, et al.
Publicado: (2016)

A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial
por: Blackwell, Kimberly, et al.
Publicado: (2016)

Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
por: Harbeck, Nadia, et al.
Publicado: (2016)

Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
por: Blackwell, K., et al.
Publicado: (2017)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
por: Sevinç, Alper, et al.
Publicado: (2018)

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
Publicado: (2021)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
por: Kamioner, Didier, et al.
Publicado: (2013)

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
por: Aapro, M., et al.
Publicado: (2016)

A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available
por: Tirelli, Umberto, et al.
Publicado: (2020)

Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis
por: Li, Edward, et al.
Publicado: (2021)

Zarzio(®), biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
por: Nahon, Sophie, et al.
Publicado: (2015)

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
por: Hegg, Roberto, et al.
Publicado: (2016)

Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis
por: Rastogi, Shruti, et al.
Publicado: (2021)

Filgrastim therapy in a child with neutropenia induced by linezolid
por: Hernández Segurado, Marta, et al.
Publicado: (2013)

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)
por: Roché, Henri, et al.
Publicado: (2018)

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product
por: Halim, Liem Andhyk, et al.
Publicado: (2018)

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019)

Days of Prophylactic Filgrastim Use to Reduce Febrile Neutropenia in Patients
por: Scott, Shane J., et al.
Publicado: (2003)

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Dipyrone/filgrastim: Neutropenia, agranulocytosis and lack of efficacy: 3 case reports
Publicado: (2021)

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
por: Al-Rabayah, Abeer A., et al.
Publicado: (2022)

Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
por: Hussaini, S. M. Qasim, et al.
Publicado: (2022)

Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018
por: Qian, Jingjing
Publicado: (2021)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018)

Immunosuppressants: COVID-19 infection, myelosuppression and febrile neutropenia: case report.
Publicado: (2020)

A Rare Case of Severe Neutropenia Due to Chikungunya Fever Which Improved With Filgrastim
por: Huq, Muhammad Rezeul, et al.
Publicado: (2021)

PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen(®)): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
por: Yao, Hsuan-Ming, et al.
Publicado: (2019)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy
por: Zecha, Judith A. E. M., et al.
Publicado: (2019)

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
por: Morrison, Vicki A., et al.
Publicado: (2007)

Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors
por: Farhan, Roiya, et al.
Publicado: (2017)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
por: Innocenti, Rolando, et al.
Publicado: (2018)

Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006
por: Hahn-Ast, Corinna, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2ijs57r56uk8i5qpoe8pcfvo7j